What AMSL Diabetes does

AMSL Diabetes, legally Australasian Medical & Scientific Limited, is a privately held Australian subsidiary of Dexcom, Inc. (NASDAQ: DXCM) that distributes continuous glucose monitoring (CGM) systems and insulin pump technology across Australia and New Zealand. Founded in 2004 and headquartered in Macquarie Park, Sydney, the company serves over 20 years as the exclusive Australian channel for Dexcom's CGM portfolio (G7, ONE+, G6) and Tandem Diabetes Care's t:slim X2 insulin pump. AMSL operates a multi-channel go-to-market combining direct e-commerce, NDSS Access Point pharmacy distribution, healthcare professional referrals, and government subsidy fulfilment. Its core products integrate Dexcom factory-calibrated CGM sensors (readings every 5 minutes) with Tandem's Control-IQ hybrid closed-loop pump, which predicts glucose 30 minutes ahead and automatically modulates insulin delivery; supporting software includes Dexcom Clarity, Glooko, the t:slim Mobile App, and Tandem Source for therapy data review.

Revenue mechanics span hardware (CGM sensors, transmitters, insulin pumps, infusion sets, cartridges, accessories), recurring consumables (AutoSoft, TruSteel, VariSoft infusion sets distributed through NDSS Access Points), and a Dexcom ONE+ subscription loyalty program offering a 7% discount with points-based vouchers. The primary customer base is people living with Type 1 diabetes accessing products through the NDSS CGM Subsidy Initiative (which expanded in 2022 to cover all eligible Australians regardless of age or concession status), with a growing Type 2 diabetes segment addressed via the Dexcom ONE+ launched in 2025. Secondary audiences include endocrinologists, diabetes educators, and GPs who prescribe devices and monitor patient data through Glooko and Tandem Source. Healthcare professional engagement is supported by an AMSL Education Hub on LearnUpon and dedicated clinical study resources. Partnerships with the DANII Foundation, Type 1 Foundation, and Willow Rose Foundation for Diabetes, plus the Dexcom Warriors advocacy initiative (over 20,000 members globally), anchor brand and community building across the Australian diabetes ecosystem.

Name

AMSL Diabetes

Legal name

Australasian Medical & Scientific Limited

Website

https://amsldiabetes.com.au

Company type

Private

Founded year

2004

Operating status

Operating

Short description

AMSL Diabetes is the Australian and New Zealand subsidiary of Dexcom that exclusively distributes Dexcom CGM systems (G7, ONE+, G6) and Tandem t:slim X2 insulin pumps to people living with Type 1 and Type 2 diabetes through NDSS subsidies, pharmacy, e-commerce, and healthcare professional channels.

Ownership category

akta.pro rank

Product category

Diabetes Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)

Keywords

• Continuous glucose monitoring
• Insulin pump therapy
• Diabetes management devices
• Hybrid closed-loop systems
• Glucose data management

Headquarters

HQ city

Macquarie Park, Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. CGM Hardware Sales: Sale of Dexcom CGM systems including sensors, transmitters, and receivers. Products include Dexcom G7, Dexcom ONE+, and Dexcom G6 systems sold directly to consumers or through subsidy programs.
2. Insulin Pump Sales: Sale of Tandem t:slim X2 insulin pumps with Control-IQ or Basal-IQ technology. Available through private health insurance, DVA, NDIS, or private purchase.
3. Consumables and Accessories: Ongoing sales of consumables including infusion sets (AutoSoft 90, AutoSoft 30, TruSteel, VariSoft), t:lock cartridges, screen protectors, pump cases, and HypoPak fast-acting glucose products through NDSS Access Points and online shop.
4. Software Subscriptions: Dexcom ONE+ loyalty program with subscription packages offering 7% discount from first delivery. Customers can earn loyalty points on sensor purchases.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

AMSL Diabetes supplies Dexcom Continuous Glucose Monitoring systems (G7, ONE+, G6) and the Tandem t:slim X2 insulin pump with Control-IQ technology to Australians with diabetes. The offering includes the core hardware devices, supporting data management software (Dexcom Clarity, Glooko, Tandem Source, t:slim Mobile App), compatible consumables such as infusion sets and t:lock cartridges, and adjunct products such as HypoPak fast-acting glucose. Distribution spans direct online sales, NDSS pharmacy Access Points, healthcare professional referrals, and Australian Government subsidy programs.

Product overview

AMSL Diabetes is a Dexcom company and the Australian distributor of diabetes management technology, operating for over 20 years. The product portfolio centres on an integrated diabetes ecosystem comprising Dexcom Continuous Glucose Monitoring (CGM) systems (G7, ONE+, G6) and the Tandem t:slim X2 insulin pump with Control-IQ hybrid closed-loop technology. These core devices work together: CGM sensors provide continuous glucose readings every 5 minutes, which the insulin pump's Control-IQ algorithm uses to predict glucose 30 minutes ahead and automatically adjust insulin delivery. Supporting the core products are Dexcom Clarity (data analytics), Glooko (data management software), the Tandem t:slim Mobile App (pump control), Tandem Source (pump data platform), and HypoPak fast-acting glucose (hypoglycemia treatment). The company also distributes compatible infusion sets and accessories.

Differentiator

Problem solved

Functional benefit

Brands

• AMSL Diabetes All-Star Program: Program designed to inspire and educate individuals on the day-to-day realities of living with type 1 diabetes by spotlighting successes and everyday triumphs of individuals within the Australian diabetes community.

Products and services

• Dexcom G7 Continuous Glucose Monitoring System Factory-calibrated Dexcom CGM system with zero fingerpricks required, insulin pump connectivity, predictive alerts, and real-time glucose readings every 5 minutes; indicated for making diabetes treatment decisions.
• Dexcom ONE+ Continuous Glucose Monitoring System Easy-to-use CGM system with essential alerts designed specifically for people living with Type 2 diabetes.
• Dexcom G6 Continuous Glucose Monitoring System CGM system with predictive low-glucose capabilities, customisable alerts and alarms, real-time data sharing, and compatibility with t:slim X2 insulin pump; registered in Australia (ARTG 330535).
• t:slim X2 Insulin Pump with Control-IQ Technology Advanced hybrid closed-loop insulin pump with Control-IQ technology that predicts glucose 30 minutes ahead and automatically adjusts insulin delivery; touchscreen interface, rechargeable battery, remote software updates, and 4-year warranty.
• t:slim X2 Insulin Pump with Basal-IQ Technology Insulin pump configuration with predictive low-glucose suspend technology that predicts glucose 30 minutes ahead and suspends insulin if expected to drop below 4.4 mmol/L, reducing low-glucose events.
• Dexcom Clarity Data analysis platform providing Dexcom users with insights including glucose highs and lows, estimated HbA1c, average glucose readings, and hypoglycemia risk assessment.
• Glooko Glucose Data Management Software Web-based glucose data management platform compatible with over 100 devices, enabling transmitting, storing, and monitoring of glucose and insulin delivery data for healthcare professionals and patients.
• Tandem t:slim Mobile App Smartphone application for t:slim X2 insulin pump users enabling viewing of insulin on board, carbs, settings, and alerts on a phone, plus wireless upload of pump data to Tandem Source.
• Tandem Source Web-based platform for uploading and viewing t:slim X2 pump data, providing three easy-to-read therapy reports for healthcare professionals and patients to review pump data, identify trends, and inform treatment decisions.
• t:slim X2 Infusion Sets and t:lock Cartridges Consumables compatible with the t:slim X2 insulin pump, including AutoSoft 90, AutoSoft 30, TruSteel, and VariSoft infusion sets, plus t:lock cartridges, distributed through NDSS Access Points and the AMSL online shop.
• HypoPak Fast Acting Glucose Kit Ready-to-use fast-acting glucose solution and kit for hypoglycemia management; gluten, dairy, egg, colour, and preservative free.

Quantifiable outcome

• Increased time in range from 63.6% to 73.6% (equivalent to 2.4 hours per day) with Control-IQ technology
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability3 records

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• DANII FoundationminorGTM or Marketing Partner · 1 October 2021AMSL Diabetes sponsors the DANII Foundation, which passionately advocates for all individuals living with Type 1 diabetes. The foundation provides CGM sponsorships for individuals who do not meet NDSS eligibility criteria and supports families through educational resources and community events.
• Type 1 FoundationminorGTM or Marketing Partner · 1 August 2021AMSL Diabetes sponsors the Type 1 Foundation, a not-for-profit charity raising awareness of Type 1 diabetes through education in schools, medical practices, and the wider community. The volunteer-based organisation aims to empower young people living with Type 1 diabetes.
• Willow Rose Foundation for DiabetesminorGTM or Marketing Partner · 1 August 2021AMSL Diabetes sponsors the Willow Rose Foundation for Diabetes, a not-for-profit organisation supporting people living with diabetes to thrive. The foundation promotes positive mental health and enables access to diabetes management technology.
• Charity TV GlobalminorGTM or Marketing Partner · 1 August 2021AMSL Diabetes sponsored Astra-Lia England participating in Charity TV Global's 'Adventure All Stars' TV series, raising funds for Diabetes Australia. The international program combines entertainment with philanthropy.
• MannKind CorporationminorChannel Partner/ Reseller/ Distributor · 1 May 2019AMSL Diabetes signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) in May 2019 to introduce their patient-focused therapies to the Australian market. The exclusive partnership was set to benefit Australian diabetes patients by offering new innovative technology solutions for diabetes management.
• Tandem Diabetes CarecoreChannel Partner/ Reseller/ Distributor · 1 August 2018AMSL Diabetes partnered with Tandem Diabetes Care in August 2018 to introduce their innovative t:slim X2 insulin pump range to the Australian market for the first time. The exclusive partnership benefits Australian Type 1 diabetes patients by offering Tandem's pump technology integrated with Dexcom CGM systems.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Abbott Diabetes Care: Abbott manufactures the FreeStyle Libre family of CGMs and competes directly with AMSL Diabetes's Dexcom G7/G6/ONE+ line for Australian CGM volume. FreeStyle Libre is the incumbent CGM in Australia and a direct substitute for Dexcom-branded sensors across both T1D and T2D.
• Medtronic Diabetes: Medtronic sells the MiniMed insulin pump portfolio and Guardian CGM in Australia, directly competing with the Tandem t:slim X2 and Dexcom CGM lines distributed by AMSL Diabetes. Medtronic is the most comparable integrated pump-plus-CGM competitor in the Australian market.
• Insulet Corporation: Insulet's Omnipod patch pump is a wearable insulin delivery competitor to the Tandem t:slim X2 distributed by AMSL Diabetes. Omnipod is establishing Australian distribution and competes for the same hybrid closed-loop patient segment served by AMSL.
• Roche Diabetes Care: Roche sells Accu-Chek blood glucose meters and insulin delivery products globally and is expanding into CGM. Its portfolio competes with the consumer-facing CGM and pump products distributed by AMSL Diabetes in Australia.
• LifeScan: LifeScan historically sold OneTouch Verio blood glucose meters and strips in Australia (now discontinued per the data). Its portfolio competes with AMSL Diabetes's glucose monitoring and insulin delivery offerings in the same Australian T1D/T2D patient population.

Emerging players

• Ypsomed: Ypsomed manufactures the mylife YpsoPump and is expanding into closed-loop diabetes management. It is an emerging pump competitor in Australia competing for share against the Tandem t:slim X2 offered by AMSL Diabetes.
• Ascensia Diabetes Care: Ascensia markets the Contour range of blood glucose monitoring systems and is pursuing diabetes digital health. It competes in the glucose-monitoring category adjacent to AMSL Diabetes's CGM-focused portfolio.
• Novo Nordisk: Novo Nordisk is the dominant insulin manufacturer globally and is rolling out connected/smart insulin pen solutions. Its emerging connected pen technology is adjacent to AMSL Diabetes's pump business and competes for insulin delivery mindshare among Australian prescribers.
• Eli Lilly: Eli Lilly is investing heavily in connected insulin delivery devices (e.g., Tempo Pen) and diabetes digital health. As a developer of insulin and connected delivery systems, it is an emerging adjacent competitor to AMSL Diabetes's pump and consumables portfolio.

Broad incumbents

• Tandem Diabetes Care: Tandem is the manufacturer of the t:slim X2 insulin pump with Control-IQ technology that AMSL Diabetes distributes exclusively in Australia. As AMSL's upstream principal, Tandem sits in an adjacent incumbency role—broader US/global scale, narrower direct Australian distribution than AMSL.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/dexcom
• YouTubeyoutube.com/user/Dexcom
• Facebookfacebook.com/Dexcom
• LinkedInlinkedin.com/company/dexcom
• Instagraminstagram.com/dexcom

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMSL Diabetes